Disease · MONDO_0005316
bacterial vaginosis
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. bacterial vaginosis. Diseases, record MONDO_0005316. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005316
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
BACT VAGINITIDES, BACT VAGINITIS, BACT VAGINOSES, BACT VAGINOSIS, Bacterial Vaginitides, Bacterial Vaginitis, Bacterial Vaginoses, Nonspecific Vaginitis, VAGINITIDES BACT, VAGINITIS BACT, VAGINOSES BACT, VAGINOSIS BACT, Vaginitides, Bacterial, Vaginitis, Bacterial, Vaginitis, Nonspecific, Vaginoses, Bacterial, Vaginosis, Bacterial
- Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METRONIDAZOLE | CHEMBL137 | Small molecule | Approval | DailyMed | 41 | 26 | 26 | Drugs and targets |
| TINIDAZOLE | CHEMBL1220 | Small molecule | Approval | DailyMed | 13 | 6 | 6 | Drugs and targets |
| SECNIDAZOLE | CHEMBL498847 | Small molecule | Approval | DailyMed, FDA and TTD | 8 | 5 | 5 | Drugs and targets |
| CLINDAMYCIN PHOSPHATE | CHEMBL3184512 | Small molecule | Approval | DailyMed | 7 | 4 | 4 | Drugs and targets |
| ASTODRIMER | CHEMBL2364665 | Small molecule | Approval | TTD | 4 | 3 | 3 | Drugs and targets |
| CLINDAMYCIN | CHEMBL1753 | Small molecule | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| FLUCONAZOLE | CHEMBL106 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| ASTODRIMER SODIUM | CHEMBL2364666 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| AZITHROMYCIN | CHEMBL529 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| DEQUALINIUM CHLORIDE | CHEMBL121663 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets12
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ESR1 | Estrogen receptor | 1 | Estrogen receptor alpha agonist | Phase 1 | https://conductscience.org/library/genes/2099 | Drugs and targets |
| NR3C1 | Glucocorticoid receptor | 1 | Glucocorticoid receptor agonist | Phase 3 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| SCN10A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6336 | Drugs and targets |
| SCN11A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/11280 | Drugs and targets |
| SCN1A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6323 | Drugs and targets |
| SCN2A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6326 | Drugs and targets |
| SCN3A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6328 | Drugs and targets |
| SCN4A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6329 | Drugs and targets |
| SCN5A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6331 | Drugs and targets |
| SCN7A | Sodium channel alpha subunit | 1 | Sodium channel alpha subunit blocker | Phase 3 | https://conductscience.org/library/genes/6332 | Drugs and targets |
1 to 10 of 12
See all 12 targetsTrials54
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02210689 | A Multi-center, Double-blind, Randomized Study, Comparing Clindamycin Phosphate Vaginal Cream 2% (Watson Laboratories, Inc.) to Clindesse® (Ther-Rx™, Clindamyin Phosphate Vaginal Cream 2%) and Both Active Treatments to a Placebo Control in the Treatment of Bacterial Vaginosis in Non-pregnant Women | Phase 3 | 604 | 2019-12-26 | BACTERIAL VAGINOSIS, Signs and Symptoms to be Evaluated and Recorded Include, Vaginal Discharge Color, Odor, and Consistency, Vulvovaginal Itching and Irritation (Subjective) Absent, Mild, Moderate, or Severe, Vulvovaginal Inflammation (Objective) Absent, Mild, Moderate, or Severe | CLINDAMYCIN PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT00334633 | Treatment of Bacterial Vaginosis (BV) With Tinidazole | Phase 4 | 593 | 2011-06-23 | Bacterial Vaginosis | METRONIDAZOLE, TINIDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02452866 | Open-Label Study to Evaluate Safety of A Single Dose of SYM-1219 | Phase 3 | 325 | 2021-04-13 | Bacterial Vaginosis | SECNIDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT04370548 | DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) | Phase 3 | 307 | 2021-07-02 | Bacterial Vaginosis | CLINDAMYCIN PHOSPHATE | Its record names the disease | ClinicalTrials.gov |
| NCT01577537 | A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis | Phase 3 | 251 | 2019-07-09 | Bacterial Vaginosis | ASTODRIMER, ASTODRIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT01577238 | A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis | Phase 3 | 250 | 2019-07-09 | Bacterial Vaginosis | ASTODRIMER, ASTODRIMER SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT02147899 | A Phase 2 Study of SYM-1219 to Treat Bacterial Vaginosis | Phase 2 | 215 | 2017-12-14 | Bacterial Vaginosis | SECNIDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02209519 | Randomized Controlled Trial of Treatment of Male Partners of Women With BV | Phase 3 | 214 | 2020-04-27 | Recurrent Bacterial Vaginosis | METRONIDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT02418845 | A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis | Phase 3 | 189 | 2021-04-13 | Bacterial Vaginosis | SECNIDAZOLE | Its record names the disease | ClinicalTrials.gov |
| NCT01867164 | A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis | Phase 3 | 160 | 2013-12-24 | Vaginitis, Infectious Vaginosis | CLINDAMYCIN, FLUOCINOLONE ACETONIDE, METRONIDAZOLE, NYSTATIN, TERCONAZOLE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 54
See all 54 trialsComparisons in its trials46
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): deaths from any cause | 0 of 203 | 0 of 103 | 306 | NCT04370548 | Trial comparisons |
| Clindamycin Phosphate Vaginal Gel, 2% vs Placebo Vaginal Gel (Universal HEC Placebo Gel): serious adverse events | 0 of 203 | 1 of 103 | 306 | NCT04370548 | Trial comparisons |
| VivaGel vs HEC Placebo: Adverse Events Potentially Related to Treatment | 17 of 126 | 9 of 123 | 249 | NCT01577537 | Trial comparisons |
| VivaGel vs HEC Placebo: serious adverse events | 0 of 126 | 0 of 123 | 249 | NCT01577537 | Trial comparisons |
| VivaGel vs HEC Placebo: Adverse Events Potentially Related to Treatment | 20 of 126 | 14 of 121 | 247 | NCT01577238 | Trial comparisons |
| VivaGel vs HEC Placebo: serious adverse events | 1 of 126 | 0 of 121 | 247 | NCT01577238 | Trial comparisons |
| VivaGel vs HEC Placebo: Number of Women With Nugent Cure at the TOC Visit | 16 of 120 | 13 of 117 | 237 | NCT01577537 | Trial comparisons |
| VivaGel vs HEC Placebo: Number of Women With Nugent Cure at the EOT Visit | 16 of 120 | 6 of 117 | 237 | NCT01577537 | Trial comparisons |
| VivaGel vs HEC Placebo: Number of Women With Clinical Cure at the Test of Cure Visit (TOC) | 34 of 120 | 33 of 117 | 237 | NCT01577537 | Trial comparisons |
| VivaGel vs HEC Placebo: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) | 68 of 120 | 25 of 117 | 237 | NCT01577537 | Trial comparisons |
1 to 10 of 46
See all 46 comparisons in its trialsPapers from its trials16
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 41382078 | DERIVED | 1 | PubMed |
| 41050878 | DERIVED | 1 | PubMed |
| 39836666 | DERIVED | 1 | PubMed |
| 37098453 | DERIVED | 1 | PubMed |
| 36475019 | DERIVED | 1 | PubMed |
| 35675606 | DERIVED | 1 | PubMed |
| 34582451 | DERIVED | 1 | PubMed |
| 34560047 | DERIVED | 1 | PubMed |
| 33383580 | DERIVED | 1 | PubMed |
| 32153879 | DERIVED | 1 | PubMed |
1 to 10 of 16
See all 16 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005316
GET https://conductscience.org/api/diseases/v1/MONDO_0005316/drugs?page=2